Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)50.66bn
  • Net income in USD15.47bn
  • Incorporated1942
  • Employees88.30k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
Array Biopharma IncDeal completed17 Jun 201917 Jun 2019Deal completed-10.71%11.37bn
Data delayed at least 15 minutes, as of May 28 2020 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Amgen, Inc.23.97bn7.68bn131.84bn23.40k17.5613.8912.825.5012.7712.7739.8916.130.38141.445.461,024,188.0012.2110.8315.1812.6779.9181.7532.0234.011.2813.400.770541.54-1.623.09-6.588.74-9.2318.91
Bristol-Myers Squibb Co31.01bn954.00m135.33bn30.00k73.932.7126.654.360.8090.80916.6522.060.37794.645.261,033,533.001.198.561.4411.2169.1672.603.1617.511.515.320.483172.4515.8910.49-30.8911.419.712.64
Eli Lilly And Co23.09bn5.53bn144.09bn33.63k24.9846.8021.566.246.036.0325.163.220.58371.564.49686,605.2013.998.7620.1012.2879.2276.6223.9716.770.86372.760.843564.423.842.6239.4514.17-2.875.65
AbbVie Inc34.06bn8.39bn158.66bn30.00k15.93--15.104.665.655.6522.94-5.020.46034.415.661,135,233.0011.409.9014.3512.7277.0677.1424.7721.343.039.091.1279.291.5710.7636.5534.62-2.0420.86
Merck & Co., Inc.48.08bn10.20bn199.51bn71.00k19.897.6114.504.153.973.9618.7310.380.57492.326.09677,211.3012.186.5016.298.2772.1767.9321.1814.300.865728.970.515688.9810.752.0953.02-3.5321.405.13
Pfizer Inc.50.66bn15.47bn212.08bn88.30k13.953.2610.014.192.742.808.9911.710.31491.215.20573,725.909.636.2712.027.6880.3779.4030.5920.230.7765--0.444573.76-3.540.850354.1511.9110.386.72
Data as of May 28 2020. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

31.87%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2020434.84m7.84%
SSgA Funds Management, Inc.as of 31 Mar 2020292.62m5.28%
BlackRock Fund Advisorsas of 31 Mar 2020270.46m4.88%
Capital Research & Management Co. (World Investors)as of 31 Mar 2020224.81m4.05%
Wellington Management Co. LLPas of 31 Mar 2020218.68m3.94%
Geode Capital Management LLCas of 31 Mar 202089.95m1.62%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202070.02m1.26%
Norges Bank Investment Managementas of 31 Dec 201959.50m1.07%
State Farm Investment Management Corp.as of 31 Mar 202056.54m1.02%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202050.86m0.92%
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.